SF Healthcare Week: Alumis' CEO Martin Babler walks us through the two successful phase 3 trials the company announced for its TYK2 last week
He discusses the TYK2 landscape and describes why Alumis believes TYK2 can be a broad class in immunology.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.